Targeting SPARC by lentivirus-mediated RNA interference inhibits cervical cancer cell growth and metastasis

BMC Cancer

Volumn 12, Issue , 2012, Pages

  Chen, Jie ^a   Shi, Dehuan ^b   Liu, Xiaoyan ^b   Fang, Shuang ^c   Zhang, Jie ^d   Zhao, Yueran ^d  

^a SHANDONG UNIVERSITY   (China)

^b SHANDONG UNIVERSITY   (China)

^c TAISHAN MEDICAL UNIVERSITY   (China)

^d SHANDONG PROVINCIAL HOSPITAL AFFILIATED TO SHANDONG UNIVERSITY   (China)

Author keywords

Apoptosis; Cervical cancer; Metastasis; Proliferation; SPARC

Indexed keywords

GELATINASE A; GELATINASE B; MESSENGER RNA; OSTEONECTIN; PROTEIN BAX; PROTEIN BCL 2; PROTEIN P21; PROTEIN P53; UVOMORULIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CANCER INHIBITION; CANCER INVASION; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL ISOLATION; CELL PROLIFERATION; CONTROLLED STUDY; FEMALE; GENE; GENE EXPRESSION; HELA CELL; HUMAN; HUMAN CELL; MOLECULAR PATHOLOGY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RNA INTERFERENCE; SPARC GENE; UTERINE CERVIX CANCER; WESTERN BLOTTING;

ANIMALS; APOPTOSIS; CADHERINS; CELL CYCLE CHECKPOINTS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; FEMALE; GENE EXPRESSION; GENE KNOCKDOWN TECHNIQUES; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HELA CELLS; HUMANS; INTEGRIN BETA CHAINS; LENTIVIRUS; MICE; MICE, NUDE; NEOPLASM METASTASIS; RNA INTERFERENCE; TUMOR SUPPRESSOR PROTEINS; UTERINE CERVICAL NEOPLASMS;

EID: 84867210241     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-12-464     Document Type: Article

References (41)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer. 2001, 37(Suppl 8):S4-66.
2. Waggoner SE. Cervical cancer. Lancet 2003, 361:2217-2225. 10.1016/S0140-6736(03)13778-6, 12842378.
3. Sheng X, Du X, Zhang X, et al. Clinical value of serum SPARC levels in early detection of recurrent squamous cell carcinoma of uterine cervix: comparison with serum SCCA, CYFRA21-1, and CEA levels. Croat Med J 2009, 50(5):455-464. 10.3325/cmj.2009.50.455, 2765737, 19839069.
4. Rao Y, Wang H, Fan L, et al. Silencing MTA1 by RNAi reverses adhesion, migration and invasiveness of cervical cancer cells (SiHa) via altered expression of p53, and E-cadherin/β-catenin complex. J Huazhong Univ Sci Technolog Med Sci 2011, 31(1):1-9. 10.1007/s11596-011-0141-9, 21336715.
5. Shibata K, Kajiyama H, Ino K, et al. Twist expression in patients with cervical cancer is associated with poor disease outcome. Ann Oncol 2008, 19(1):81-85.
6. Termine JD, Kleinman HK, Whitson SW, et al. Osteonectin, a bone-specific protein linking mineral to collagen. Cell 1981, 26:99-105. 10.1016/0092-8674(81)90037-4, 7034958.
7. Bornstein P, Sage EH. Matricellular proteins: extracellular modulators of cell function. Curr Opin Cell Biol 2002, 14(5):608-616. 10.1016/S0955-0674(02)00361-7, 12231357.
8. Chlenski A, Cohn SL. Modulation of matrix remodeling by SPARC in neoplastic progression. Semin Cell Dev Biol 2010, 21(1):55-65. 10.1016/j.semcdb.2009.11.018, 19958839.
9. Tai IT, Tang MJ. SPARC in cancer biology: its role in cancer progression and potential for therapy. Drug Resist Updat 2008, 11(6):231-246. 10.1016/j.drup.2008.08.005, 18849185.
10. Albini A, Iwamoto Y, Kleinman HK, et al. A rapid in vitro assay for quantitating the invasive potential of tumor cells. Cancer Res 1987, 47(12):3239-3245.
11. Framson PE, Sage EH. SPARC and tumor growth: where the seed meets the soil?. J Cell Biochem 2004, 92:679-690. 10.1002/jcb.20091, 15211566.
12. Hsiao YH, Lien HC, Hwa HL, et al. SPARC (osteonectin) in breast tumors of different histologic types and its role in the outcome of invasive ductal carcinoma. Breast J 2010, 16(3):305-308. 10.1111/j.1524-4741.2009.00899.x, 20210803.
13. Lien HC, Hsiao YH, Lin YS, et al. Molecular signatures of metaplastic carcinoma of the breast by large-scale transcriptional profiling: identification of genes potentially related to epithelial-mesenchymal transition. Oncogene 2007, 26(57):7859-7871. 10.1038/sj.onc.1210593, 17603561.
14. Horie K, Tsuchihara M, Nakatsura T. Silencing of secreted protein acidic and rich in cysteine inhibits the growth of human melanoma cells with G arrest induction. Cancer Sci 2010, 101(4):913-919. 10.1111/j.1349-7006.2009.01476.x, 20100207.
15. Girotti MR, Fernández M, López JA, et al. SPARC promotes cathepsin B-mediated melanoma invasiveness through a collagen I/α2β1 integrin axis. J Invest Dermatol 2011, 131(12):2438-2447. 10.1038/jid.2011.239, 21850018.
16. Lau CP, Poon RT, Cheung ST, et al. SPARC and Hevin expression correlate with tumour angiogenesis in hepatocellular carcinoma. J Pathol 2006, 210(4):459-468. 10.1002/path.2068, 17029219.
17. Le Bail B, Faouzi S, Boussarie L, et al. Osteonectin/SPARC is overexpressed in human hepatocellular carcinoma. J Pathol 1999, 189(1):46-52. 10.1002/(SICI)1096-9896(199909)189:1<46::AID-PATH392>3.0.CO;2-X, 10451487.
18. Thomas R, True LD, Bassuk JA, et al. Differential expression of osteonectin/SPARC during human prostate cancer progression. Clin Cancer Res 2000, 6(3):1140-1149.
19. Chan SK, Griffith OL, Tai IT, et al. Meta-analysis of colorectal cancer gene expression profiling studies identifies consistently reported candidate biomarkers. Cancer Epidemiol Biomarkers Prev 2008, 17(3):543-552. 10.1158/1055-9965.EPI-07-2615, 18349271.
20. Wiese AH, Auer J, Lassmann S, et al. Identification of gene signatures for invasive colorectal tumor cells. Cancer Detect Prev 2007, 31(4):282-295. 10.1016/j.cdp.2007.07.003, 17936523.
21. Nagai MA, Gerhard R, Fregnani JH, et al. Prognostic value of NDRG1 and SPARC protein expression in breast cancer patients. Breast Cancer Res Treat 2011, 126(1):1-14. 10.1007/s10549-010-0867-2, 20369286.
22. Koblinski JE, Kaplan-Singer BR, VanOsdol SJ, et al. Endogenous osteonectin/SPARC/BM-40 expression inhibits MDA-MB-231 breast cancer cell metastasis. Cancer Res 2005, 65(16):7370-7377. 10.1158/0008-5472.CAN-05-0807, 16103089.
23. Said N, Motamed K. Absence of host-secreted protein acidic and rich in cysteine (SPARC) augments peritoneal ovarian carcinomatosis. Am J Pathol 2005, 167(6):1739-1752. 10.1016/S0002-9440(10)61255-2, 1613196, 16314484.
24. Said N, Najwer I, Motamed K. Secreted protein acidic and rich in cysteine (SPARC) inhibits integrinmediated adhesion and growth factor-dependent survival signaling in ovarian cancer. Am J Pathol 2007, 170(3):1054-1063. 10.2353/ajpath.2007.060903, 1864881, 17322388.
25. Atorrasagasti C, Malvicini M, Aquino JB, et al. Overexpression of SPARC obliterates the in vivo tumorigenicity of human hepatocellular carcinoma cells. Int J Cancer 2010, 126(11):2726-2740.
26. Said N, Frierson HF, Chernauskas D, et al. The role of SPARC in the TRAMP model of prostate carcinogenesis and progression. Oncogene 2009, 28(39):3487-3498. 10.1038/onc.2009.205, 19597474.
27. Liang JF, Wang HK, Xiao H, et al. Relationship and prognostic significance of SPARC and VEGF protein expression in colon cancer. J Exp Clin Cancer Res 2010, 29:71. 10.1186/1756-9966-29-71, 2895582, 20565704.
28. Yang E, Kang HJ, Koh KH, et al. Frequent inactivation of SPARC by promoter hypermethylation in colon cancers. Int J Cancer 2007, 121(3):567-575. 10.1002/ijc.22706, 17397030.
29. Sova P, Feng Q, Geiss G, et al. Discovery of novel methylation biomarkers in cervical carcinoma by global demethylation and microarray analysis. Cancer Epidemiol Biomarkers Prev 2006, 15(1):114-123. 10.1158/1055-9965.EPI-05-0323, 16434596.
30. Kahn SL, Ronnett BM, Gravitt PE, et al. Quantitative methylation-specific PCR for the detection of aberrant DNA methylation in liquid-based Pap tests. Cancer 2008, 114(1):57-64. 10.1002/cncr.23258, 2648805, 18181097.
31. Zhang LQ, Jiang F, Xu L, et al. The Role of Cyclin D1 Expression and Patient's Survival in Non-Small-Cell Lung Cancer: A Systematic Review with Meta-Analysis. Clin Lung Cancer 2012, 13(3):188-195. 10.1016/j.cllc.2011.10.003, 22133292.
32. Naryzhny SN. Proliferating cell nuclear antigen: a proteomics view. Cell Mol Life Sci 2008, 65(23):3789-3808. 10.1007/s00018-008-8305-x, 18726183.
33. Liebermann DA, Hoffman B, Vesely D. p53 induced growth arrest versus apoptosis and its modulation by survival cytokines. Cell Cycle 2007, 6:166-170. 10.4161/cc.6.2.3789, 17264673.
34. Gartel AL. p21 (WAF1/CIP1) and cancer: a shifting paradigm?. Biofactors 2009, 35(2):161-164. 10.1002/biof.26, 19449443.
35. Fenouille N, Robert G, Tichet M, et al. The p53/p21Cip1/ Waf1 pathway mediates the effects of SPARC on melanoma cell cycle progression. Pigment Cell Melanoma Res 2011, 24(1):219-232. 10.1111/j.1755-148X.2010.00790.x, 20955243.
36. Kelly PN, Strasser A. The role of Bcl-2 and its pro-survival relatives in tumourigenesis and cancer therapy. Cell Death Differ 2011, 18(9):1414-1424. 10.1038/cdd.2011.17, 3149740,3149740, 21415859.
37. Fenouille N, Puissant A, Tichet M, et al. SPARC functions as an anti-stress factor by inactivating p53 through Akt-mediated MDM2 phosphorylation to promote melanoma cell survival. Oncogene 2011, 30(49):4887-4900. 10.1038/onc.2011.198, 21685937.
38. Robert G, Gaggioli C, Bailet O, et al. SPARC represses E-cadherin and induces mesenchymal transition during melanoma development. Cancer Res 2006, 66(15):7516-7523. 10.1158/0008-5472.CAN-05-3189, 16885349.
39. Smit DJ, Gardiner BB, Sturm RA. Osteonectin downregulates E-cadherin, induces osteopontin and focal adhesion kinase activity stimulating an invasive melanoma phenotype. Int J Cancer 2007, 121(12):2653-2660. 10.1002/ijc.23039, 17724718.
40. Kunigal S, Gondi CS, Gujrati M, et al. SPARC-induced migration of glioblastoma cell lines via uPA-uPAR signaling and activation of small GTPase RhoA. Int J Oncol 2006, 29(6):1349-1357. 1661847, 17088972.
41. McClung HM, Thomas SL, Osenkowski P, et al. SPARC Upregulates MT1-MMP Expression, MMP-2 Activation, and the Secretion and Cleavage of Galectin-3 in U87MG Glioma Cells. Neurosci Lett 2007, 419(2):172-177. 10.1016/j.neulet.2007.04.037, 1978544, 17490812.